News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
85% of bladder cancer patients avoided surgery with durvalumab boost
Phase 2 trial shows adding immunotherapy durvalumab to chemoradiation kept muscle-invasive bladder cancer at bay for 85% of patients at one year — without removing the bladder.
Eli Lilly's in vivo CAR-T shows safer profile than AstraZeneca rival in early myeloma trial
Kelonia's KLN-1010 delivered responses in all 18 patients with manageable toxicity, but durability data remains sparse and prior BCMA therapy exposure is unclear.
Eli Lilly's RET drug cuts recurrence risk 83% in early lung cancer
Retevmo reduced event-free survival risk by 83% in a 151-patient adjuvant NSCLC trial. The win opens a rare but underexplored patient population — if genetic testing keeps pace.
Roche's breast cancer drug wins FDA priority review by late 2026
Giredestrant cut recurrence risk by 30% in Phase III trials. The oral therapy targets early-stage ER-positive breast cancer where cure odds are highest—FDA decision expected by November 2026.
AbbVie wins EC approval for Aquipta migraine acute treatment
European Commission approves Aquipta (atogepant) for acute migraine in adults. AbbVie now offers both acute and preventive migraine treatments in the EU.
Contraline raises $92.5M to test first male contraceptive pill in 2027
Google Ventures-backed Contraline is funding Phase III trials of NES/T Gel, a daily topical male contraceptive. If successful, it could be the first hormonal birth control approved for men.
$3.6B in biotech funding fuels AI drug design and clinical trials
Isomorphic Labs, Apogee Therapeutics, and Avalo raised $3.6 billion combined in May 2026. Here's where the money went and what it means for drug pipelines.
Big Pharma Spending $240B to Replace Blockbusters Before Patents Expire
Patent cliffs are forcing pharmaceutical giants into a bidding war for biotech assets. M&A hit $240 billion last year as companies like Merck and Pfizer race to plug revenue gaps from expiring drugs.
Brain Reference Map From 54K Scans Shows White Matter Changes Across Life
USC researchers built lifespan charts for brain neural pathways using diffusion MRI data from 54,583 people. The tool detects disease patterns in dementia, schizophrenia risk, and genetic conditions—and it's publicly available.
Fulcrum kills sickle cell drug after FDA cites cancer risk from rival therapy
Fulcrum Therapeutics halted pociredir development following FDA concerns about secondary blood cancers observed with Ipsen's Tazverik. The decision wipes out $1.5B in projected peak sales and triggers a 51% stock drop.
Measles vaccine T cells cross-react to deadly Nipah virus in first study
Scientists at La Jolla Institute found that immune cells primed by MMR vaccination can recognize Nipah virus, suggesting a path to broad paramyxovirus vaccines. Here's what the data shows and what happens next.
Spatial Imaging Reveals Why Antibodies Fail Inside Solid Tumors
A platform from Vanderbilt and Stanford visualizes drug delivery barriers in human tumors, showing stromal tissue blocks antibody penetration. Here's what oncology teams should know.